Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
Investing.com -- Ultragenyx Pharmaceutical (TADAWUL:2070) Inc. (NASDAQ:RARE) reported first-quarter results that fell short of analyst expectations, sending shares down 5.9% in after-hours trading on Monday.
The biopharmaceutical company, focused on rare genetic diseases, posted adjusted earnings per share of -$1.57, missing the consensus estimate of -$1.56. Revenue for the quarter came in at $139 million, below analyst projections of $145.39 million but up 28% YoY.
Crysvita, Ultragenyx’s treatment for X-linked hypophosphatemia, generated $103 million in revenue, representing 25% growth compared to the same period last year. Dojolvi revenue was $17 million, while Evkeeza brought in $11 million as the company continues its launch outside the United States.
"In the first quarter, our commercial team continued expanding our base of revenue around the world," said Emil D. Kakkis, M.D., Ph.D., CEO and president of Ultragenyx.
Despite the earnings miss, Ultragenyx reaffirmed its full-year 2025 guidance. The company expects total revenue between $640 million and $670 million, with Crysvita revenue of $460 million to $480 million and Dojolvi revenue of $90 million to $100 million.
Ultragenyx reported a net loss of $151 million for the quarter, or $1.57 per share, compared to a loss of $171 million, or $2.03 per share, in the same period last year.
The company ended the quarter with $563 million in cash, cash equivalents, and marketable debt securities. Net cash used in operations was $166 million for the period.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.